Onesource Specialty Pharma

    ONESOURCE
    Pharma
    ₹1,586.20
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹18,190 Cr

    P/E
    19.37
    Day range
    ₹1,563.40 – ₹1,592.40
    52-week range
    ₹1,057.00 – ₹1,917.80
    Volume
    1.59 L
    Open
    ₹1,580.80
    Prev close
    ₹1,580.80

    Latest results · Q2 FY27(consolidated)Revenue ₹965 Cr+156.9%Profit ₹82 Cr+686.7%Margin 8.5%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      Promoter pledge went up

      38.79% of promoter shares pledged, up from 37.23% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 47 / 100

    Factor percentiles

    Value51
    Quality43
    Momentum45
    Low volatility51

    Derived metrics

    Earn. yield
    5.2%
    Graham no.
    ₹106.72
    vs Graham
    -93.3%
    ROE ÷ P/B
    -0.4%
    12-1 mom.
    -21.4%
    Return / vol
    -0.27
    Magic Formula
    #442
    Piotroski
    5/6
    FCF yield
    -3.1%
    PEG
    0.03

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Onesource Specialty PharmaONESOURCE₹18,190 Cr19.373.13-1.3%1.0%32.0%0.30+37.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3h ago

    Headlines about Onesource Specialty Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    1617.0
    Price / Book
    3.07
    ROE (FY26)
    -1.3%
    ROCE (latest year)
    1%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹1,543.4
    Price above
    50-day
    ₹1,536.1
    Price above
    200-day
    ₹1,548.82
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +231.6%
    Revenue YoY (Sep 2026)
    +37.2%
    Profit YoY (Sep 2026)
    +470.0%
    Operating margin
    32.0%
    Net margin
    11.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -200 Cr0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026-45%0%45%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY22FY23FY24FY25FY26-100%-75%-50%-25%0%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales5673292334393426327376290428449516
    YoY Sales growth————————-26———
    Expenses6776228257251243239269273336326353
    Operating Profit-10-36477142183881061792123163
    OPM %-19%-3.8%22%23%36%43%27%28%6%21%27%32%
    Other Income-743-1-1-94223-220-1
    Interest262042454633273438233135
    Depreciation202068686968687070727275
    Profit before tax-130-40-47-37-6783-46-9302053
    Tax %0%0%-88%12%4%-19%-96%-83%-5%-1630%-23%-9%
    Net Profit-130-40-6-42-6998010-8952557
    EPS in Rs————₹-6.02₹8.61₹-0.02₹0.92₹-7.74₹0.40₹2.18₹5.01

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days177

    +139 days since Mar 2021

    Inventory Days438

    +351 days since Mar 2021

    Days Payable307

    -455 days since Mar 2021

    Cash Conversion Cycle308

    +945 days since Mar 2021

    Working Capital Days-6

    +2386 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 3.12 times its book value
    • Company has low interest coverage ratio.
    • Company has a low return on equity of -2.63% over last 3 years.
    • Promoters have pledged 38.8% of their holding.
    • Company has high debtors of 177 days.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +131%
    3 Years
    +232%
    TTM
    +11%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +8%
    3 Years
    +24%
    TTM
    -92%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    -10%

    Return on Equity

    10 Years
    —
    5 Years
    -10%
    3 Years
    -3%
    Last Year
    -1%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter29.93%30.48%30.48%30.47%-0.01 pp
    FII19.24%17.50%19.19%19.45%+0.26 pp
    DII18.80%20.61%23.37%24.20%+0.83 pp
    Public32.01%31.40%26.95%25.86%-1.09 pp

    Filed with NSE for Sept 2026: promoters 30.47%, public 69.53%

    Analysts & fund holdings

    100%
    100% recommend buy
    4 analysts cover the stock
    Valuation vs Biotechnology
    P/E19.4 vs 45.1
    Sector P/B6.03

    Who holds the shares, quarter by quarter

    Mutual funds 13.76% (+0.78 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters30.5%
    • Foreign institutions19.5%
    • Mutual funds13.8%
    • Insurance4.1%
    • Other domestic institutions6.3%
    • Retail9.9%
    • Others15.9%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Motilal Oswal Large & Midcap Fund3.31%3.04%-0.32 pp
    Motilal Oswal Flexi Cap Fund2.13%2.92%+0.14 pp
    Motilal Oswal ELSS Tax Saver Fund0.94%3.65%-0.04 pp
    360 ONE Focused Fund0.91%2.55%-0.01 pp
    Axis Small Cap Fund0.79%0.49%-0.00 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    Avg
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    42.9%
    Downside volatility
    42.9%
    Worst 5% of days
    3.7%
    Average of that tail
    5.8%
    Max drawdown (1Y)
    41.1%
    Below its peak
    16.1%

    Against the market

    Beta vs Nifty 50
    -0.08
    Correlation
    -0.03
    Relative strength (3M)
    -2.1%
    ATR (14)
    3.7%

    Return

    Return 1M
    +12.7%
    Return 3M
    +1.8%
    Return 6M
    -12.4%
    Return 1Y
    -11.5%
    vs 200-day average
    +2.4%

    Momentum

    RSI (14)
    55.5
    MACD histogram
    4.24
    Stochastic %K
    33.2
    ADX (14)
    29.1
    +DI / −DI
    25.1 / 15.8
    Money flow index
    38.7

    Participation

    Delivery (20d avg)
    49.8%
    vs its 60-day baseline
    -0.8 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    +0.2%
    52-week position
    61 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    -₹561 Cr
    FCF yield
    -3.1%
    Cash conversion
    -0.12
    Accruals ratio
    -0.010
    Net debt
    ₹1,741 Cr
    Net debt / equity
    0.29
    EV / sales
    9.34
    PEG
    0.03
    Capex intensity
    40.0%
    Revenue CAGR
    72.4%
    Profit CAGR
    -11.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹44.8 Cr
    6 buys · ₹44.8 Cr
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    TENSHI PHARMACEUTICALS PRIVATE LIMITED
    Promoters · Market Purchase
    Buy85,000₹1.0 Cr6 Feb 2026
    TENSHI PHARMACEUTICALS PRIVATE LIMITED
    Promoters · Market Purchase
    Buy2,05,000₹23.9 Cr6 Feb 2026
    PRONOMZ VENTURES LLP
    Promoter Group · Market Purchase
    Buy33,906₹4.0 Cr6 Feb 2026
    Tenshi Pharmaceuticals Private Limited
    Promoters · Market Purchase
    Buy75,000₹8.7 Cr6 Feb 2026
    PRONOMZ VENTURES LLP
    Promoter Group · Market Purchase
    Buy45,000₹5.1 Cr6 Feb 2026
    Tenshi Pharmaceuticals Private Limited
    Promoters · Market Purchase
    Buy2,00,000₹2.1 Cr6 Feb 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended September 30, 2026

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Board Meeting Intimation For Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended September 30, 2026.

    Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve OneSource Specialty ....

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 900 Equity shares of Re. 1 each under ONESOURCE ESOP 2021 on September 25, 2026

    Insider Trading / SAST
    Closure of Trading Window

    Closure of trading window for the quarter ended September 30, 2026

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results along with Scrtuinizer's report for the 19th AGM

    Company Update
    Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

    Intimation of appointment of M/s BSR and Co. LLP as the Statutory Auditors of the Company for a term of 5 consecutive years.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 19th AGM (2nd AGM Post Listing) of the Company

    Company Update
    General Update

    Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of the investor presentation

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper advertisement confirming the dispatch of the notice convening the 19th AGM of the Company and Remote e-voting

    AGM/EGMPrice-sensitive
    Notice Of The 19Th AGM Dated September 23, 2026

    Intimation of the Notice of the 19th AGM (2nd AGM after listing), to be held on September 23, 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Report for the FY 2026

    Others
    Reg. 34 (1) Annual Report.

    Annual Report for FY 2025-26

    Others
    Reg. 34 (1) Annual Report.

    Annual Report for FY 2025-26

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Investors called scheduled on September 03, 2026 at 10:00 AM.

    Filed with BSE (scrip 544292); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 27 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Onesource Specialty Pharma: common questions

    Answered from the figures on this page.

    Onesource Specialty Pharma last traded at ₹1,586.20 (NSE, as of 18 Nov 2026). The last session moved it up 0.34%.

    Onesource Specialty Pharma is valued at about ₹18,190 crore (NSE, as of 18 Nov 2026).

    Onesource Specialty Pharma trades at a price-to-earnings ratio of 19.37 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Onesource Specialty Pharma has traded between ₹1,057.00 and ₹1,917.80 over the past 52 weeks, to 18 Nov 2026. It is currently 61% of the way up that range.

    Onesource Specialty Pharma (ONESOURCE) is classified under Pharma on this site's screener.